Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. [electronic resource]
Producer: 20030911Description: 2917-23 p. digitalISSN:- 0250-7005
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Disease-Free Survival
- Docetaxel
- Drug Administration Schedule
- Epirubicin -- administration & dosage
- Female
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Heart Diseases -- chemically induced
- Humans
- Middle Aged
- Paclitaxel -- administration & dosage
- Stroke Volume -- drug effects
- Taxoids
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.